Most fine-needle aspiration procedures for thyroid nodules can be safely delayed for 6 months or longer during the COVID-19 pandemic; data show such delays do not influence the long-term prognosis for ...
Please provide your email address to receive an email when new articles are posted on . In a series of thyroid nodules from adults in Ireland, the false-negative rate of an initial benign thyroid fine ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. With a few notable exceptions, the majority of fine needle aspiration (FNA) biopsies of thyroid ...
FNA is recommended for all palpable solitary or dominant nodules, independent of size. FNA is preferred over thyroid scan or ultrasonography as the initial diagnostic test for thyroid nodules. However ...
MicroRNAs act as negative regulators of protein-coding genes (including oncogenes and tumor suppressors); their dysregulation can lead to carcinogenesis. Nikiforova and colleagues have now shown that ...
A phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC). This is an ASCO Meeting Abstract from the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc., (Nasdaq: VCYT) announced today new data that show the company’s Afirma Xpression Atlas (XA) can identify clinically relevant gene fusions ...
Verywell Health on MSN
Thyroid nodules: Causes and treatment
Medically reviewed by Isabel Casimiro, MD, PhD Key Takeaways Thyroid nodules are common and are not cancerous 95% of the time ...
Fine needle aspiration (FNA) plays a vital role in the evaluation of patients with thyroid nodules, in terms of distinguishing benign, non-neoplastic thyroid nodules that may be conservatively managed ...
Photodynamic therapy (PDT) with mTHPC in the palliation of advanced head and neck cancer in patients who have failed prior therapies and are unsuitable for radiotherapy, surgery or systemic ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company’s RNA sequencing-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results